Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 80,091 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 80,091 shares of Personalis stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.02, for a total transaction of $882,602.82. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $2,600,565.72. This represents a 25.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

NASDAQ:PSNL opened at $11.40 on Friday. The firm’s 50 day simple moving average is $6.86 and its 200 day simple moving average is $8.10. Personalis, Inc. has a one year low of $3.84 and a one year high of $11.85. The company has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Equities research analysts expect that Personalis, Inc. will post -1.06 EPS for the current year.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after acquiring an additional 1,655 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares in the last quarter. Howland Capital Management LLC grew its stake in shares of Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PSNL. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. BTIG Research dropped their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, Morgan Stanley dropped their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.